Characterization of transgenic mouse lines for labeling type I and type II afferent neurons in the cochlea

Pankhuri Vyas1, Jingjing Sherry Wu1,2,3, Adrian Jimenez4, Elisabeth Glowatzki1,2 & Paul Albert Fuchs1,2

The cochlea is innervated by type I and type II afferent neurons. Type I afferents are myelinated, larger diameter neurons that send a single dendrite to contact a single inner hair cell, whereas unmyelinated type II afferents are fewer in number and receive input from many outer hair cells. This strikingly differentiated innervation pattern strongly suggests specialized functions. Those functions could be investigated with specific genetic markers that enable labeling and manipulating each afferent class without significantly affecting the other. Here three mouse models were characterized and tested for specific labeling of either type I or type II cochlear afferents. Nos1CreER mice showed selective labeling of type I afferent fibers, Slc6a4-GFP mice labeled type II fibers with a slight preference for the apical cochlea, and Drd2-Cre mice selectively labeled type II afferent neurons nearer the cochlear base. In conjunction with the Th2ACreER and CGRPα-EGFP lines described previously for labeling type II fibers, the mouse lines reported here comprise a promising toolkit for genetic manipulations of type I and type II cochlear afferent fibers.

Spiral ganglion neurons (SGNs) receive inputs from hair cells, mechanoreceptors of the cochlea, to encode acoustic information into action potentials that travel into the central nervous system (CNS). SGNs are divided into two major groups based on their morphology and cochlear innervation pattern. Type I SGNs are larger diameter, myelinated neurons that constitute ~95% of the total auditory nerve fibers. They send a single dendrite to contact one inner hair cell (IHC). The remaining 5% are smaller diameter, unmyelinated type II afferent fibers that contact numerous outer hair cells (OHCs) as they spiral hundreds of microns towards the cochlear base1,2. Type I SGNs are responsible for encoding the salient parameters of sound3. Type II SGN function remains an area of active inquiry, with recent studies supporting a role in signaling tissue damage4,5.

Genetically engineered mouse lines that allow selective targeting and manipulation of specific neuronal groups are valuable tools for in vivo functional studies, fate-mapping during development, regeneration experiments and more. Since type II afferent fibers are few in number, small in caliber and unmyelinated, mouse genetic tools will be especially useful for defining their function in vivo. A variety of mouse lines have been described that label SGNs, for example: Shh (Sonic hedgehog)-Cre6, Neurog1 (Neurogenin1)-Cre8, Neurog1-CreERT29, Bhlhb5-Cre8, PV (Parvalbumin)-Cre10. However, Cre drivers such as these don’t distinguish type I from type II SGNs. The present work shows that all type I, but not type II SGNs express the enzyme neuronal nitric oxide synthase, making this a specific marker for future studies of type I SGNs.

Previous work has shown that tyrosine hydroxylase (TH) is preferentially expressed by apically-located type II afferents, while calcitonin gene related peptide alpha (CGRPα) is preferentially expressed by type II afferents in the cochlear base11,12. In the present work, two additional mouse lines are shown to specifically label type II SGNs, the serotonin transporter (SERT/Slc6a4) and a subunit of the dopamine receptor, Drd2. Furthermore,
these expression patterns also reveal ‘tonotopic’ heterogeneity within the type II population. This strengthens the speculation that apical and basal type II afferents may serve distinct functions.

**Results**

**Neuronal Nitric Oxide Synthase (Nos1CreER) specifically labels type I but not type II afferent neurons in the cochlea.** Nitric oxide is a gaseous neurotransmitter that has been implicated in many aspect of CNS function, including neuron structural plasticity, synaptic plasticity, regulation of blood flow and release of other neurotransmitters12,13. The expression of neuronal nitric oxide synthase (nNOS), the enzyme responsible for nitric oxide synthesis in neurons, was examined in pre-hearing (postnatal day (P)7–9) and hearing mice (P30–45) by crossing a knock-in Nos1CreER mouse line with a tdTomato reporter line (Ai9). Upon induction with tamoxifen, the expression of reporter protein (tdTomato) was observed in SGNs throughout all cochlear turns (Fig. 1a,b). Upon closer examination of the organ of Corti, bouton endings of tdTomato-expressing SGNs were found in the IHC region (Fig. 1c) supporting their identity as type I afferent neurons that innervate IHCs. To investigate further the identity of the labeled neurons, co-immunolabeling was performed with β-tubulin 3 (TuJ1), which preferentially labels type I versus type II SGNs at young adult ages15. Most of the tdTomato-expressing SGNs were immunopositive for TuJ1 (Fig. 1d, also see Supplemental Video), confirming their identity as type I afferent neurons. It should be noted that since Nos1CreER is an inducible Cre line, the recombinase efficacy is dependent on the dose of tamoxifen. We observed that a small fraction (~10%) of type I SGNs were not labeled (Fig. 1e,f,g) at the dose used in this experiment. Also, when the reporter expression of Nos1CreER; Ai9 mice was induced with tamoxifen at pre-hearing ages (P2–5), a few non-neuronal cells were also found to express tdTomato in the osseous spiral lamina at P7 (Table 1) (see Supplemental Fig. S1), which were not observed when tamoxifen was injected after P10 and cochleas were analyzed between P30–45. As a control, Nos1CreER; Ai9 mice without tamoxifen injection showed no labeling in the cochlea (see Supplemental Fig. S1). Immunolabeling for nNOS has been reported.
previously in different cell types in the cochlea, including but not limited to the inner and outer hair cells, SGNs and olivocochlear efferents. However, the labeling pattern observed here was specific to the SGNs, and not found in hair cells or olivocochlear efferents. This discrepancy in the labeling patterns between nNos antibody and Nos1CreER; Ai9 mice could be due to various factors, such as the lack of antibody specificity, low expression of CreER in other cell types at the time of tamoxifen induction, or the timing difference between the Nos1 gene expression and nNos protein accumulation. The present results show that when induced in the second postnatal week, the Nos1CreER mouse line can be used to label type I cochlear afferents specifically.

### Serotonin Reuptake Transporter (Slc6a4-GFP) specifically labels type II cochlear afferents.

Serotonin reuptake transporter (SERT) is a membrane protein encoded by the Slc6a4 gene that recycles the neurotransmitter serotonin from the synaptic cleft into presynaptic neurons in a sodium-dependent manner. In the auditory periphery, immunoabel of SERT has been reported in the olivocochlear efferent system, auditoryafferent fibers of developing marmoset and embryonic (E15.5) rat cochlear nucleus. Serotonergic synaptic activity also has been demonstrated in the cochlea by the use of biochemical inhibitors. Here, Slc6a4-GFP (also known as SERT-GFP), a BAC transgenic mouse line expressing SERT under the Slc6a4 promoter was used to study the expression of SERT in the cochlea. Whole mount fluorescence microscopy of Slc6a4-GFP mouse cochleas showed the expression of GFP in fibers in the organ of Corti along the three rows of outer hair cells from which short branches with bouton endings connect with the OHCs; a pattern typical for type I afferents (Fig. 2a). When co-immunostained with β-tubulin 3 (TuJ1), GFP-expressing neurons did not overlap with TuJ1-positive type I SGNs (Fig. 2b–e), again supporting their identity as type II, but not type I, cochlear afferent neurons.

The expression pattern of Slc6a4-GFP cochleas was examined in pre-hearing (P7–9) and hearing mice (P30–45). GFP-expressing SGNs were counted in bins by dividing the cochlear whole mounts into 10 segments along the tonotopic axis using ImageJ, as described previously. Representative images of apical, mid and basal turns of cochlea with labeled SGNs in pre-hearing mice are shown in Fig. 3a–d. GFP-expressing neuronal somata (arrows) were observed in Slc6a4-GFP mouse cochleas at both ages, although occasion ally small-diameter cells (arrows) were observed in Slc6a4-GFP mouse cochleas at both ages that were easily distinguished from SGNs by their size. Since SERT is expressed in platelets and involved in regulating blood pressure, these are likely to be platelets. Consistent with that conclusion, the putative platelets were found aligned within blood vessels. Consistent with the observations using Slc6a4-GFP mice, another knock-in mouse line, Slc6a4CreER (see Materials and Methods), also specifically labeled type II fibers when crossed with the Ai9 reporter line and analyzed at ages between P7–45 (see Supplementary Fig. S4). Similar to Slc6a4-GFP, cochleas in Slc6a4CreER; Ai9 mice also labeled non-neuronal cells in the osseous spiral lamina and stria vascularis, however, no expression was observed in the platelets (Table 1) (see Supplementary Fig. S4). Finally, we examined the cochlear labeling pattern of Slc6a4-Cre BAC transgenic mice (see Materials and Methods). This line showed a less specific labeling pattern, that included expression in both type I and type II SGNs and cochlear efferents, and therefore the expression was not investigated further.

### Drd2-Cre mouse line labels type II afferents in the mid-basal region of the cochlea.

Dopamine is a neurotransmitter of lateral olivocochlear efferents that regulate type I afferent signaling. Previous studies have reported the expression of dopamine receptor subtypes (D1–5) in spiral ganglion neurons by RT PCR and immunohistochemical analysis. Type II-like morphology of fibers and their terminal boutons on OHCs could clearly be visualized in the mid and basal turns of Drd2-Cre; Ai9 mouse cochleas at P30 (Fig. 4a). When Drd2-Cre; Ai3 (R26SL-EYFP) cochleas were co-immunostained with α3 Na+/K+ ATPase, which is expressed specifically in myelinated type I afferents and medial efferents but not in unmethylated type II afferents and lateral efferents, SGNs positive for EYFP (i.e., Drd2-Cre driven) or α3 Na+/K+ ATPase were mutually exclusive, as shown in the spiral ganglion region (Fig. 4b–e).

The expression pattern of Drd2-Cre was examined in pre-hearing (P7–9) and hearing mice (P30–45). Interestingly, the expression of Drd2-Cre was found only in the mid and basal type II afferents, although occasionally also in a few medial efferents in the apical cochlea (Fig. 5b, arrow) and presumably gla cells in the osseous spiral lamina (see Supplemental Fig. S5; Table 1). This expression gradient in type II SGNs across cochlea spiral is illustrated for pre-hearing cochlear whole mounts (Fig. 5a–d) and is similar for cochleas from hearing animals (Fig. 5e).

| Mouse line     | SGN expression | Cochlear Region | Age Range Examined | Expression in other cell types                                      | References |
|----------------|----------------|-----------------|--------------------|---------------------------------------------------------------------|------------|
| Nos1CreER      | Type I         | All             | P7–P45             | Non-neuronal cells in the osseous spiral lamina observed when Tamoxifen injected between P2–P7 | This work  |
| TheCreER       | Type II        | Apex, mid       | P7–P60             | Lateral efferents                                                   | refs11,12  |
| CgrpCreEGFP    | Type II        | Mid, base       | P7–P45             | Medial efferents, Lateral efferents, type I SGNs at prehearing ages | refs13,14  |
| Slc6a4-GFP     | Type II        | All             | P7–P45             | Platelets, Non-neuronal cells in stria vascularis                    | refs15,16  |
| Slc6a4Cre      | Type II        | All             | P7–P45             | Non-neuronal cells in the spiral osseous lamina and the stria vascularis | This work  |
| Drd2-Cre       | Type II        | Mid, base       | P7–P45             | Sporadic labeling of apical medial efferents and lateral efferents   | This work  |

Table 1. Mouse models targeting type I versus type II SGNs.
Figure 2. 

Slc6a4-GFP specifically labels type II SGNs. (a) Labeled type II afferent fibers (green) in the apical turn of a one-month-old Slc6a4-GFP mouse cochlea. Arrow indicates type II afferent boutons. Inner and outer hair cells are labeled with Myosin VI (Myo6) antibody (blue). (b) Antibody against TuJ1 (red) labels type I SGNs (asterisk) but not GFP-expressing type II SGNs (arrowhead). (c,d,e) Magnified images of the area marked by dashed outlines in b. (c) Type I SGNs labeled with TuJ1 antibody (red). (d) Type II SGNs expressing GFP (green). (e) Merged image of d and e. Scale bars represent 10 μm (a,b) and 5 μm (c,d,e).

Figure 3. Slc6a4-GFP expression varies along the cochlea. Representative images from the apical turn (a,b), mid turn (c), and basal turn (d) showing the expression of Slc6a4-GFP in pre-hearing type II SGNs. Representative somata indicated by arrowheads, while platelets are indicated by arrows. Cochlear whole mounts from Slc6a4-GFP mice were analyzed before (P6–8, n = 5) and after the onset of hearing (P30–35, n = 6). (e) Each cochlear turn was divided into 10 bins of equal length along the cochlear spiral and the number of labeled SGNs in each cochlear bin were counted. Shaded areas represent standard deviations. Scale bars represent 100 μm for all images.
Comparison of expression between different molecular markers for type II afferents. Thus far, four molecular/genetic markers have been shown to label type II afferent neurons, described here or in Wu et al.12. To better illustrate and compare the tonotopic distribution of the labeled type II SGNs using these different strategies, graphical representations of these distributions at hearing age are shown in Fig. 6. Similar to Th and Cgrpα (also known as Calca)12, Slc6a4-GFP and Drd2-Cre also showed specific expression gradients along the cochlear coil (as summarized in Fig. 6c). Both TH antibody labeling as well as the distribution of Slc6a4-GFP labeled type II SGNs showed an apical preference, although the peak of TH labeling was found further apically (Fig. 6a). Slc6a4-GFP labeling is largely absent from the apical and basal extremes, but otherwise is distributed along the cochlear spiral, with a maximum at approximately 1/3 of the cochlear length from the apical end (Fig. 6a). Both Cgrpα-EGFP and Drd2-Cre showed distributions biased towards the cochlear base. However, the Drd2-Cre labeled roughly half as many type II neurons compared to Cgrpα-EGFP (P30, Fig. 6b). Given that the expression of Cgrpα is downregulated in type I SGNs during the first postnatal month12, there could be an overestimation for the number of type II SGNs based on Cgrpα-EGFP labeling in one-month-old mice.

To assess further type II afferent heterogeneity and to understand better how to utilize the different molecular and genetic markers for manipulating type II afferents, labeling patterns were compared at the level of individual SGNs. For example, two genetic markers with similar tonotopic distribution might be expressed by separate populations of type II SGNs. However, type II SGNs that co-express candidate genes were found in the overlapping regions. While type II SGNs expressing Drd2-Cre; Ai9 and Slc6a4-GFP are largely segregated along the cochlear coil, individual SGNs co-expressing Slc6a4-GFP and Drd2-Cre; Ai9 can still be found in the cochlear middle turn (Fig. 7a,a1,a2,a3 asterisk). Drd2-Cre and the previously reported Cgrpα-EGFP mouse lines both label basal type II afferents. Cross-bred Drd2-Cre; Ai9; Cgrpα-EGFP mice showed co-expression of the reporter proteins in some SGNs (asterisks in Fig. 7b,b1,b2,b3). 'Apical' reporters were examined in Slc6a4-GFP mouse cochleas labeled with antibodies against TH (Fig. 7c). Most of the type II SGNs in the cochlear apical region were co-labeled by both markers (Fig. 7c1,c2,c3). SGNs expressing TH and Drd2-Cre were largely restricted to apex or base, respectively. However, a few co-labeled SGNs could be found in the middle turn (Fig. 7d,d1,d2,d3, asterisk). Finally, as previously reported, TH and Cgrpα-EGFP expressing neurons could show co-expression in the middle turn of the cochlea12. We were not able to look for co-expression of Cgrpα-EGFP and Slc6a4-GFP, because both mouse lines express the same reporter protein.

Discussion

This work is part 3 of a series of studies to identify and validate mouse genetic tools for labeling and separately manipulating type I and type II afferents, the spiral ganglion neurons (SGNs) of the mammalian cochlea. As for previous studies in this series11,12 genetically modified mice obtained from commercial vendors and local laboratories were examined for expression of reporter proteins in cochlear afferents. This work describes a mouse with CreER coupled to the Nos1 promoter that drove reporter expression specifically in type I but not type II SGNs. In addition, three mouse lines, Slc6a4-GFP, Slc6a4Cre and Drd2-Cre could be used to target type II, but not type I, SGNs. Between tested genes, different apical-to-basal expression patterns and different amounts of overlap were found between markers, suggesting that subpopulations of type II neurons exist.
Does the labeling of specific groups of SGNs by these different mouse lines represent the endogenous expression pattern of these genes? *Nos1*^CreER^ was constructed by inserting CreER into the endogenous *Nos1* locus. Therefore, its expression most likely reflects the actual gene expression. The presence of nitric oxide synthase (NOS) has been described in cochlear tissue, including SGNs \(^{17,18,32,33}\). *Slc6a4-GFP* and *Drd2-Cre* were both made by random insertion of bacterial artificial chromosomes (BAC) containing the promoter and regulatory sequence of these two genes. Depending on where the BAC integrates in the genome, the expression may or may not reflect the endogenous pattern. However, the labeling patterns of these two lines have been validated in the central nervous system (CNS) by the GENSAT project (www.gensat.org). The specific expression of SERT in type II afferent neurons has been replicated with another *Slc6a4Cre* knock-in line. For the *Drd2-Cre* line, the expression patterns in the CNS have been further validated by *in-situ* hybridization \(^{34}\). Additional supporting evidence comes from three recently published single-cell RNA sequencing (scRNAseq) studies on SGNs \(^{35–37}\). NOS1 was identified in all three studies as a gene that is expressed in type I but not type II SGNs. In addition, *Nos1* was expressed in all three subtypes of type I SGNs (based on principal component clustering), corresponding with the present observation of universal expression of reporter protein in type I SGNs. Similarly, TH and SERT were identified as marker genes for the type II SGNs in all three studies. Evidence for differential CGRP\(_{\alpha}\) expression in type II versus type I SGNs was reported in two of the studies. CGRP\(_{\alpha}\) was expressed at higher levels in type II SGNs than in type I SGNs \(^{37}\), and was among the genes expressed differentially by type I and type II SGNs \(^{36}\). *Drd2* expression was not reported in these publications, possibly due to low RNA levels, but the online data repository \(^{37}\) showed that *Drd2* is expressed at a low level in one of the subtypes of type I SGNs. The discrepancy between the scRNAseq result and the *Drd2-Cre* mouse line labeling could be due to various factors. It is possible that basal type II afferent neurons express *Drd2* during development and downregulate its expression in adults. Alternatively, because the *Drd2-Cre* mouse line is constructed by random insertion of BAC in the genome, which are prone to internal rearrangements, the reporter expression induced by this line may not reflect endogenous expression of *Drd2* gene in the cochlea. To sum up, the expression patterns of NOS1, TH, CGRP\(_{\alpha}\) and SERT genes in SGNs in these transgenic mouse lines is largely consistent with scRNAseq data. We do see different types of unidentified cells.
in Nos1CreER, Drd2-Cre and SERT-Cre expressing mouse cochleas that were not traceable in the literature. These unidentified cell types were found in different regions of the cochlea, have different shapes and molecular footprints and need further analysis for identification. Whether basal type II afferents express Drd2 mRNA or protein awaits further investigation. It bears repeating that even without such confirmation, these mouse lines still can serve as experimental models for the study of SGNs.

Does the expression of these marker genes in the SGNs tell us anything about function? Nitric oxide regulates voltage-gated ion channels of hair cells and possibly can act as a retrograde transmitter to increase the probability of transmitter release from efferent terminals on inner hair cells prior to the onset of hearing. Soluble guanylyl cyclase, the principal target of NO, is expressed in olivocochlear efferents. Do the expression of TH, SERT and CGRP suggest that type II afferent neurons use dopamine, serotonin and CGRP as neurotransmitters? Because they are all suggested olivocochlear efferent neurotransmitters, previous studies of these neurotransmitters have focused logically on efferent neurons (in addition to glutamate transmission from hair cells) but made no mention of type II cochlear afferents. Dopamine release from lateral olivocochlear efferents can suppress the activity of type I afferents but the cellular effects of CGRP and 5-HT remain to be determined. Expression of TH is not in itself a guarantor of dopaminergic transmission. If the Drd2-Cre labeling represents the endogenous expression, the opposing patterns of TH and Drd2 along the tonotopic axis further complicates any functional interpretation. Using RT-PCR, Drd2 receptor transcripts were identified in the OHCs. Whether type II afferents could release dopamine in a retrograde fashion to act on OHCs requires further investigation.

Thus, while these expression patterns may prove useful for future experimental strategies, they don't change our present understanding of OHC to type II afferent synaptic function. Synaptic currents evoked in type II afferents by high potassium depolarization of cochlear tissue are due to glutamate release from outer hair cells that acts on AMPA and possibly kainate receptors. Besides those synaptic signals, type II afferents respond to extracellular ATP with P2X and P2Y type receptors. Intracellular recording from OHCs has yet to reveal any synaptic currents other than those due to acetylcholine release from cholinergic medial olivocochlear terminals. If dopamine, or CGRP or 5-HT are released from type II afferent terminals in the cochlear nucleus, their actions there remain to be determined.

A hallmark of the cochlea is the ‘tonotopic’ organization of macro- and microscopic features that underlie acoustic frequency selectivity. For example, the basilar membrane increases in stiffness from apex to base, giving rise to the mechanically-tuned traveling wave described by von Békésy. The neuronal innervation of the cochlea also varies along the tonotopic axis. Afferent and efferent innervation is highest in mid regions of the cochlea (serving the most sensitive range of hearing) and there is a general tendency for greater numbers of both afferent and efferent contacts in the higher frequency cochlear base.

Since individual type I afferents contact a single inner hair cell in the mature cochlea, one might predict these neurons to be specialized according to their acoustic frequency selectivity. Indeed, there is already evidence supporting tonotopic variation of type I SGNs. For example, intracellular recording from dissociated type I afferents...
Figure 7. Co-expression of different molecular markers in type II afferents. (a) Organ of Corti from the mid turn of a triple transgenic mouse Drd2-Cre; Ai9; Slc6a4-GFP cochlea (P30). Drd2-Cre (arrowhead, red) and Slc6a4-GFP (arrow, green) can express individually or together in single neurons. (a1) Magnified area of inset from a, separated into individual channels in (a2,a3). Some SGNs were labeled by both mouse lines (asterisks, a1, a2, a3), some only by Slc6a4-GFP (arrows) and some only by Drd2-Cre (arrowheads). (b) Drd2-Cre; Ai9; CGRPα-EGFP can express individually or together in single neurons in the basal turn (b1) Magnified area of inset in (b), separated into individual channels in (b2,b3). Arrow indicates neurons expressing CGRPα-EGFP (green), arrowhead indicates neurons expressing Drd2-Cre (red) and asterisk indicates neurons co-expressing Drd2-Cre and CGRPα-EGFP (yellow). (c) SGNs in a P30 Slc6a4-GFP mouse cochlear apex labeled with TH antibody. Slc6a4-GFP (green) and tyrosine hydroxylase (TH, red) are co-expressed by most of the neurons in the cochlear apex and mid turn. (c1) Magnified area of inset in c, separated into individual channels in (c2,c3). (d) Organ of Corti from the mid turn of a transgenic mouse Drd2-Cre; Ai3 (P7) immunostained with TH.
showed that basic membrane properties differed between those originating apically versus those from the cochlear base\[^{38}\]. Moreover, within each of the three major subgroups of type I SGNs clustered by scRNAseq, there was tonotopic variation of expression for a subset of genes\[^{39}\]. Taken together these results support the hypothesis that type I SGNs may fall into functional subgroups; with minor functional differences along the tonotopic axis.

Type II afferents are known to vary morphologically along the cochlear length\[^{59}\]. Possibly due to the relatively small number of type II afferent neurons, very few studies have addressed heterogeneity among type II SGNs. Similarly, the recent scRNAseq studies also did not provide additional insights regarding subgroups within type II SGNs. However, expression patterns of different transgenic mouse lines have revealed ‘tonotopic’ heterogeneity among type II SGNs. Previous studies showed that promoters for TH and CGRP\[^{\alpha}\] were active in apical and basal type II afferents, respectively\[^{11,12}\]. In the present work the promoters for SERT and DRD2 also drove tonotopic gradients in reporter protein expression by type II afferents. Each of these four genetic drivers had distinctive patterns of expression along the cochlea’s tonotopic axis. TH predominates in the apical half, SERT is expressed in a bell-shaped expression gradient with a bias toward the cochlear apex, while CGRP\[^{\alpha}\] and DRD2 appear preferentially in the cochlear base. In mid-cochlear regions of overlap, CGRP\[^{\alpha}\] and TH can be co-expressed by single type II neurons\[^{12}\]. The present work also shows that single type II SGNs can co-express more than one label in regions of overlap, suggesting that these are not mutually exclusive populations. Rather, it suggests that the expression patterns found here reveal some underlying genetic differentiation related to cochlear position.

Why do type II afferents differ along the cochlea’s tonotopic axis? Comparisons to somatosensory afferents might be illuminating. Pain-sensing C-fibers of skin express CGRP and this signaling molecule plays a role in damage-triggered inflammation\[^{38}\]. The preferential expression of CGRP by type II afferents in the higher frequency base of the cochlea would be consistent with the greater sensitivity of this region to acoustic trauma and so might serve an analogous function. In contrast, TH is expressed by unmyelinated low threshold mechanoreceptors (C-LTMRs) of skin\[^{11}\] that play a role in ‘emotional touch’\[^{62}\] and TH predominates in the low frequency cochlear apex where tissue trauma is less likely. It will be of interest to explore further the tonotopic diversity of type II afferents.

Methods

All animal experiments were carried out in accordance to the guidelines approved by the Johns Hopkins Animal Care and Use Committee (ACUC). Mice from both sexes were used in experiments. No obvious differences were observed between males and females in this study. For every finding, at least three experiments with animals from three litters were performed.

Mouse Models. The mouse line Drd2-Cre \([\text{B6.FVB}(\text{Cg})-\text{Tg}(\text{Drd2-crc})\text{ER44Gsat/Mmucd})\] (RRID:MMRRC_032108-UCD) was bred on the C57BL/6J background. It was generated by random insertion of a bacterial artificial chromosome (BAC) containing the regulatory sequences of Drd2 gene followed by the Cre cassette as part of the GENSAT project\[^{40}\]. The Slc6a4-GFP \([\text{Tg}(\text{Slc6a4-GFP})\text{P55Gsat/Mmucd})\] (RRID:MMRRC_030692-UCD0) line, Slc6a4-Cre \([\text{Tg}(\text{Slc6a4-crc})\text{ET127Gsat/Mmucd})\] (RRID:MMRRC_017261-UCD) and the CGRP\[^{\alpha}\]-EGFP \([\text{Tg}(\text{Calc-a-EGFP})\text{FG104Gsat/Mmucd; RRMRC_011187-UCD})\] line were generated by GENSAT project using a similar strategy and obtained on mixed background. Nos1\[^{\text{GFP}}\] \([\text{B6.129S-Nos1}^{\text{GFP}}/\text{Mmucd})\] (The Jackson Laboratories, #014541) is on C57BL/6J background and was generated by inserting a CreER\[^{\text{T2}}\] fusion gene into the Nos1 locus. Slc6a4\[^{\text{GFP}}\] \([\text{B6.129(Cg)-Slc6a4}^{\text{GFP}}/\text{Mmucd})\] (The Jackson Laboratories, #015540) is obtained on C57BL6 background and was generated by targeting a nuclear-localized Cre recombinase upstream of the first coding ATG of the Slc6a4 gene. The Cre reporter lines Ai3 \([\text{B6.Cg- Gt}(\text{ROSA})26Sortm3(CAG-EGFP)Hze/J, #007903]\) on C57BL6 background, Ai9 \([\text{B6.Cg- Gt}(\text{ROSA})26Sortm9(CAG-tdTomato)Hze/J, #007909]\) on C57BL6 background and Ai32 \([\text{B6.Cg- Gt}(\text{ROSA})26Sortm32(CAG-COPAH)345/EYFPHze/J, #024109]\) on mixed background were purchased from The Jackson Laboratories.

Tamoxifen Injection. Tamoxifen stock (Sigma #T5648) was prepared by dissolving tamoxifen in corn oil (Sigma #C8267) at a concentration of 10 mg/ml for sonication at room temperature (2 h). Stock solutions were stored at 4°C in the dark and were used within 4 days of preparation. For studying the phenotype of postnatal day (P) 7 animals, tamoxifen was administered through intrastragic injection\[^{64}\] at P3 and P5 (0.2 mg each time) using an insulin syringe with an ultrafine needle (BD, 22 G). For analysis at 3–7 weeks, tamoxifen (1 mg) was administered by intra-peritoneal injections in the second postnatal week.

Tissue Preparation and Immunofluorescence. Mice from postnatal day 5 to 40 were deeply anesthetized by isoflurane inhalation and decapitated. Temporal bones were removed and post-fixed in electron microscopic grade 4% paraformaldehyde (Electron Microscopy Sciences, Hatfield, PA) through the round and oval windows. The tissue was post-fixed for 1 h at room temperature (RT), rinsed with phosphate buffer solution (1X PBS), and dissected into apical, medial, and basal turns. Temporal bones from mice older than P25 were decalcified in 0.2 M ethylenediaminetetraacetic acid (EDTA) in PBS overnight at 4°C after fixation. After rinsing with 1X PBS, cochlear turns were incubated in 30% sucrose for 10 min, coomblized by quick freeze (−80°C) and thaw (37°C) and then washed with 1X PBS. The cochlear turns were then incubated in a blocking and permeabilizing buffer (10% normal donkey serum, 0.5% Triton X-100 in 1X PBS) for 1 h at RT. Primary antibodies were applied...
in incubation buffer (5% normal donkey serum, 0.25% Triton X-100 and 0.01% NaNO₃ in 1x PBS) for 48 hours at RT. Tissue was then rinsed in 1X PBS three times and incubated with Alexa Fluor-conjugated secondary antibodies (Molecular Probes) used at 1:1000 dilution for 1–2 h at room temperature. Cochlear tissue was rinsed three times with 1X PBS and mounted in FluorSave antifade mounting medium (CalBiochem, San Diego, CA). Primary antibodies used in this study include goat anti-GFP (1:5000, Sigen #AB0020-200) rabbit anti-DsRed polyclonal antibody (1:1000, Takara #632496), mouse anti-NKARl3 (1:300, Thermo Fisher Scientific #MA3-915), mouse anti-TuJ1 (1:300, Biolegend #801201), rabbit anti-Myosin VI (1:500, Sigma-Aldrich #M5187), mouse anti-Myosin VIIa (1:200–500, DSHB #MYO7A), rabbit anti-TH (1:500, Millipore #657012-15UG), mouse anti-CD34 (1:50, BioLegend #343505).

Image Acquisition and Quantification. Images were acquired on a LSM700 confocal microscope (Zeiss Axio Imager Z2) using 10× and 40× N.A. 1.30 oil immersion objectives. Images were processed using Fiji (RRID: SCR_002285), Photoshop CS6 (Adobe) and illustrator CS6 (Adobe). Quantification was carried out using Zen software (Zeiss) and Photoshop CS6 (Adobe). Quantification of spiral ganglion neuron numbers in each cochlear turn was performed as described previously. Supplementary Video was made using syGlass system from IstoVisio Inc. (https://www.sysglass.io/).

Data Availability
Most of the data generated or analyzed during this study are included in this published article. All datasets from the current study are available from the corresponding authors on reasonable request.

References
1. Berglund, A. M. & Ryugo, D. K. Hair cell innervation by spiral ganglion neurons in the mouse. J Comp Neurol 255, 560–70, https://doi.org/10.1002/cne.902550408 (1987).
2. Jagger, D. J. & Housley, G. D. Membrane properties of type II spiral ganglion neurones identified in a neonatal rat cochlear slice. J Physiol 552, 525–533, https://doi.org/10.1113/jphysiol.2003.052589 (2003).
3. Young, E. D. Neural representation of spectral and temporal information in speech. Philos Trans R Soc Lond B Biol Sci 363, 923–945, https://doi.org/10.1098/rstb.2007.2151 (2008).
4. Liu, C., Glowatzki, E. & Fuchs, P. A. Unmyelinated type II afferent neurons report cochlear damage. Proc Natl Acad Sci USA 112, 14723–14727, https://doi.org/10.1073/pnas.1515228112 (2015).
5. Flores, E. N. et al. A non-canonical pathway from cochlea to brain signals tissue-damaging noise. Curr Biol 25, 606–612, https://doi.org/10.1016/j.cub.2015.01.009 (2015).
6. Cox, B. C., Liu, Z., Lagerde, M. M. & Zuo, J. Conditional gene expression in the mouse inner ear using Cre-loxP. J Assoc Res Otolaryngol 13, 295–322, https://doi.org/10.1007/s11455-012-0324-3 (2012).
7. Liu, Z., Owen, X., Zhang, L. & Zuo, J. Dynamic expression pattern of Sonic hedgehog in developing cochlear spiral ganglion neurons. Dev Dyn 239, 1674–1683, https://doi.org/10.1002/dvdy.22302 (2010).
8. Appler, J. M. et al. Gata3 is a critical regulator of cochlear wiring. J Neurosci 33, 3679–3691, https://doi.org/10.1523/JNEUROSCI.4703-12.2013 (2013).
9. Roudondjian, E. J., Appler, J. L. & Goodrich, L. V. Auditory neurons make stereotyped wiring decisions before maturation of their targets. J Neurosci 27, 14078–14088, https://doi.org/10.1523/JNEUROSCI.3765-07.2007 (2007).
10. Marrs, G. S. & Sproul, G. A. Embryonic assembly of auditory circuits: spiral ganglion and brainstem. J Physiol 590, 2391–2408, https://doi.org/10.1113/jphysiol.2011.226886 (2012).
11. Vyas, P., Wu, J. S., Zimmerman, A., Fuchs, P. & Glowatzki, E. Tyrosine Hydroxylase Expression in Type II Cochlear Afferents in Mice. J Assoc Res Otolaryngol 18, 139–151, https://doi.org/10.1007/s11455-016-0591-7 (2017).
12. Wu, J. S., Vyas, P., Glowatzki, E. & Fuchs, P. A. Opposing expression gradients of calcitonin-related polypeptide alpha (Calca/ Cgppalpha) and tyrosine hydroxylase (Th) in type II afferent neurons of the mouse cochlea. J Comp Neurol 526, 425–438, https://doi.org/10.1002/cne.24341 (2018).
13. Calabrese, V. et al. Nitric oxide in the central nervous system: neuroprotection versus neurotoxicity. Nature Reviews Neuroscience 8, 766, https://doi.org/10.1038/nrn2214 (2007).
14. Cosenza, M. et al. In Vitamins & Hormones Vol. 96 (ed. Gerald Litwack) 79–125 (Academic Press, 2014).
15. Xing, Y. et al. Age-related changes of myelin basic protein in mouse and human auditory nerve. PLoS One 7, e34500, https://doi.org/10.1371/journal.pone.0034500 (2012).
16. Franz, P., Hauser-Kronberger, C., Bock, P., Quint, C. & Baumgartner, W. D. Localization of nitric oxide synthase I and III in the cochlea. Acta Otolaryngol 116, 726–731 (1996).
17. Shen, J., Harada, N., Nakazawa, H. & Yamashita, T. Involvement of the nitric oxide-cyclic GMP pathway and neuronal nitric oxide synthase in ATP-induced Ca2+ signalling in cochlear inner hair cells. Eur J Neurosci 21, 2912–2922, https://doi.org/10.1111/j.1460-9586.2005.04135.x (2005).
18. Shen, J. et al. Role of nitric oxide on ATP-induced Ca2+ signaling in outer hair cells of the guinea pig cochlea. Brain Res 1081, 101–112, https://doi.org/10.1016/j.brainres.2005.12.129 (2006).
19. Riemann, R. & Reuss, S. Nitric oxide synthase in identified olivocochlear projection neurons in rat and guinea pig. Hear Res 135, 181–189 (1999).
20. Coleman, J. A., Green, E. M. & Gouaux, E. X-ray structure and mechanism of the human serotonin transporter. Nature 532, 334–339, https://doi.org/10.1038/nature17629 (2016).
21. Gil-Loyzaga, P., Bartolome, V., Vicente-Torres, A. & Carricondo, F. Serotoninergic innervation of the organ of Corti. Acta Otolaryngol 1120, 128–132 (2000).
22. Lebrand, C., Gaspar, P., Nicolas, D. & Hornung, J. P. Transitory uptake of serotonin in the developing sensory pathways of the common marmoset. J Comp Neurol 499, 677–689, https://doi.org/10.1002/cne.21137 (2006).
23. Narbour-Neme, N., Pavone, L. M., Avalone, L., Zhuang, X. & Gaspar, P. Serotonin transporter transgenic (SERTCre) mouse line reveals developmental targets of serotonin specific reuptake inhibitors (SSRI's). Neuropharmacology 55, 994–1005, https://doi.org/10.1016/j.neuropharm.2008.08.020 (2008).
24. Vicente-Torres, M. A., Davila, D., Bartolome, M. V., Carricondo, F. & Gil-Loyzaga, P. Biochemical evidence for the presence of serotonin transporters in the rat cochlea. Hear Res 182, 43–47 (2003).
25. Lorente de No, R. The sensory endings in the cochlea. Laryngoscope 47, 373–377 (1937).
26. Mercado, C. P. & Kilic, F. Molecular mechanisms of SERT in platelets: regulation of plasma serotonin levels. Mol Interv 10, 231–241, https://doi.org/10.1121/mi.10.4.6 (2010).
We thank Dr. David Linden (Johns Hopkins University, Baltimore, MD) for the Slc6a4-GFP and Slc6a4-Cre mice and Dr. David Ginty (Harvard Medical School, Boston, MA) for the CGRPα−EGFP mice. This work was supported by NICHD R01DC006476 and R01DC12957 to EG, NICHD R01DC016559 to PAF, NICHD P30 DC005211 to the Center for Hearing and Balance, the John Mitchell, Jr. Trust, the David M. Rubenstein Fund for Hearing Research and the John E. Bordley Professorship (PAF).

Acknowledgements
Author Contributions
P.V. and J.S.W. designed the studies; P.V. performed experiments; P.V., J.S.W. and A.J. analyzed data. P.V., J.S.W., P.A.F. and E.G. discussed results, wrote and edited the manuscript.

Additional Information
Supplementary information accompanies this paper at https://doi.org/10.1038/s41598-019-41770-5.

Competing Interests: The authors declare no competing interests.

Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2019